MyFinsight
Home
Blog
About
Net income (loss)
$162.849M
(450.77%↑ Y/Y)
Receivable from
collaboration partner
-$40.247M
(75.61%↑ Y/Y)
Stock-based compensation
$14.037M
(-43.20%↓ Y/Y)
Prepaid expenses and
other assets
-$4.217M
(-306.21%↓ Y/Y)
Proceeds from issuance of
common stock upon...
$9.743M
(-34.38%↓ Y/Y)
Accrued expenses and
other payables
$4.19M
(150.01%↑ Y/Y)
Deferred revenue
$3.377M
(132.15%↑ Y/Y)
Non-cash lease expense
$0.444M
(-60.95%↓ Y/Y)
Depreciation
$0.397M
(-26.89%↓ Y/Y)
Net cash provided by
operating activities
$219.052M
(126.80%↑ Y/Y)
Net cash provided by
financing activities
$9.743M
(-32.19%↓ Y/Y)
Canceled cashflow
$10.706M
Net increase in
cash, cash...
$226.365M
(217.22%↑ Y/Y)
Canceled cashflow
$2.43M
Accounts payable
-$4.9M
(-403.97%↓ Y/Y)
Contract asset
$3.366M
(-84.90%↓ Y/Y)
Accretion of discount on
marketable securities
$1.046M
(-75.11%↓ Y/Y)
Other non-current
assets
$0.832M
Operating lease liability
-$0.56M
(-638.46%↓ Y/Y)
Other
-$0.002M
Proceeds from maturities
of marketable...
$132.414M
(-43.88%↓ Y/Y)
Net cash provided by
(used in) investing...
-$2.43M
(93.86%↑ Y/Y)
Canceled cashflow
$132.414M
Purchase of marketable
securities
$134.676M
(-52.11%↓ Y/Y)
Purchases of property and
equipment
$0.168M
(-87.63%↓ Y/Y)
Back
Back
Cash Flow
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)
source: myfinsight.com